The evidence-based approach in health policy and health care delivery

Social Science and Medicine

Volumn 51, Issue 6, 2000, Pages 859-869

  Niessen, Louis W ^a   Grijseels, Els W M ^a   Rutten, Frans F H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Cost effectiveness; Evidence based policy; Guidelines; Health determinants

Indexed keywords

HEALTH CARE; HEALTH POLICY; POLICY STRATEGY; SERVICE PROVISION;

COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH STATUS; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; REVIEW; SOCIOECONOMICS;

EID: 0034666820     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(00)00066-6     Document Type: Article

References (99)

1. Barendregt J.J.M., Bonneux L.G.A. Degenerative disease in an aging population - models and conjectures. 1998;Erasmus University, Rotterdam.
2. Borst-Eilers E. Progress report of the Minister of Health to the Chairman of the National Assembly on Medical Technology Assessment and Quality Assurance in Medical Care. 1997;National Assembly, The Hague.
3. Briggs A., Sculpher M. Sensitivity analysis in economic evaluation: A review of published studies. Health Economics. 4:1995;355-371.
4. Brundtland G.H. Environment and health. Europe's partnerships can be a model. British Medical Journal. 318:1999;1635-1636.
5. Burnand B. Clinical practice guidelines - a public health perspective. European Journal of Public Health. 9:1999;83-85.
6. Buxton M. Measurement of the costs and benefits of the heart transplant programmes at Harefield and Papworth Hospitals. 1985;HMSO, London.
7. CCPHTA, 1997. Guidelines for economic evaluation of pharmaceuticals. Canadian Co-ordinating Office for Health Technology Assessment, Ottawa, Canada.
8. Cumper G.E. Determinants for health levels in developing countries. 1984;Research Studies Press, New York.
9. Daniels N., Light D.W., Caplan R.L. Benchmarks of fairness for health care reform. 1996;Oxford University Press, New York.
10. Breast cancer screening (Forrest Report). 1986;HMSO, London.
11. Guidelines for authors and peer reviewers of economic submissions to the BMJ. British Medical Journal. 313:1996;. Appendix.
12. Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W. Methods for the economic evaluation of health care programmes. 1997;Oxford Medical Publications, Oxford.
13. Dutch Institute for Health Care Improvement, 1999. [Treatment and prevention of coronary heart diseases by lowering the concentration of plasma-cholesterol]. Dutch Institute for Health Care Improvement/Dutch Heart Foundation. Van Zuiden Communications, Alphen a/d Rijn, the Netherlands.
14. Dutch Institute for Health Care Improvement, 2000. [Stroke Guidelines 2000]. Dutch Institute for Health Care Improvement/Dutch Heart Foundation van Zuiden Communications, Alphen a/d Rijn, the Netherlands.
15. Elsinga E., Rutten F.F. Economic evaluation in support of national health policy: The case of The Netherlands. Social Science and Medicine. 45:1997;605-620.
16. Feder G., Eccles M., Grol R., Griffiths C., Grimshaw J. Clinical guidelines: Using clinical guidelines. British Medical Journal. 318:1999;728-730.
17. Field M.J., Lohr K.N. Clinical practice guidelines: Directions for a new program. 1990;National Academy Press, Washington, DC.
18. Freemantle N., Mason J. Not playing with a full DEC: Why development and evaluation committee methods for appraising new drugs may be inadequate. British Medical Journal. 318:1999;1480-1482.
19. Frenk J., Bobadilla J.L., Stern C., Frejka T., Lozano R. Elements for a theory of the health transition. Chen L.C., Kleinman A., Ware N.C. Health and social change in international perspective. 1993;Harvard University Press, Boston, MA.
20. GFHR, 1999. The 10/90 report on health research - Promoting research to improve the health of the people. Global Forum for Health Research, Geneva.
21. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-effectiveness in health and medicine. 1996;Oxford University Press, Oxford.
22. Gold M.R., Franks P., McCoy K.I., Fryback D.G. Toward consistency in cost-utility analyses: Using national measures to create condition-specific values. Medical Care. 36:1998;778-792.
23. Grimshaw J.M., Russell I.T. Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations. Lancet. 342:1993;1317-1322.
24. Gross C.P., Anderson G.F., Powe N.R. The relation between funding by the National Institutes of Health and the burden of disease. New England Journal of Medicine. 340:1999;1881-1887.
25. Gunning L.J., Hagen J.H. Avoidable burden of illness: How much can prevention contribute to health? Social Science and Medicine. 24:1987;945-951.
26. Hailey D., Menon D. A short history of INAHTA. International Network of Agencies for Health Technology Assessment. International Journal of Technology Assessment in Health Care. 15:(1):1999;236-242.
27. Haycox A., Bagust A., Walley T. Clinical guidelines - The hidden costs. British Medical Journal. 318:1999;391-393.
28. Health Insurance Council, 1999. [Doelmatigheid van zorg; gewikt and gewogen] [in Dutch]. Health Insurance Council, Amstelveen.
29. Holloway R.G., Benesch C.G., Rahilly C.R., Courtright C.E. A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke. 30:1999;1340-1349.
30. Hurst J. The impact of health economics on health policy in England and the impact of health policy on health economics, 1972-1997. Health Economics. 7:1998;S47-S62.
31. Hurwitz B. Legal and political considerations of clinical practice guidelines. British Medical Journal. 318:1999;661-664.
32. Kaplan G.A., Pamuk E.R., Lynch R.D., Coher R.D., Balfour J.L. Inequality in income and mortality in the United States: Analysis of mortality and potential pathways. British Medical Journal. 312:1996;999-1003.
33. Kassirer J.P., Angell M. The Journal's policy on cost-effectiveness analyses. New England Journal of Medicine. 331:1994;669-671.
34. Kassirer J.P., Angell M. Evaluation and management guidelines - Fatally flawed. New England Journal of Medicine. 339:1998;1697-1698.
35. Krieger N., Birn A.E. A vision of social justice as the foundation of public health: Commemorating 150 years of the spirit of 1848. American Journal of Public Health. 88:1998;1603-1606.
36. Kwakani N.C. Performance in living standards: An international comparison. Journal of Development Economics. 41:1993;307-336.
37. Lalonde, M. 1974. A new perspective on the health of Canadians. Ministry of National Health and Welfare, Ottawa, Canada.
38. Langley P.C. The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics. 9:1996;341-352.
39. Langley P.C., Martin R.E. Managed care guidelines for the economic evaluation of pharmaceuticals. American Journal of Managed Care. 3:1997;1013-1021.
40. Lerer L.B. How to do (or not to do)...Health impact assessment. Health Policy and Planning. 14:1999;198-203.
41. Lerer L.B., Lopez A.D., Kjellstrom T., Yach D. Health for all: Analysing health status and determinants. World Health Statistics Quarterly. 51:1998;7-20.
42. Mackenbach, J. P., 1988. Mortality and medical care: Studies of mortality by cause of death in The Netherlands and other European countries. Department of Public Health, Erasmus University, Rotterdam.
43. Mackenbach J.P. Health care expenditure and mortality from amenable conditions in the European Community. Health Policy. 19:1991;245-255.
44. Mackenbach J.P., Gunning-Schepers L.J. How should interventions to reduce inequalities in health be evaluated? Journal of Epidemiology and Community Health. 51:1997;359-364.
45. Mason J., Eccles M., Freemantle N., Drummond M. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy. 47:1999;37-52.
46. McGinnis J.M., Lee P.R. Healthy People 2000 at mid decade. Journal of the American Medical Association. 273:1995;1123-1129.
47. McGuire A., Parkin D., Hughes D., Gerard K. Econometric analyses of national health expenditures: can positive economics help to answer normative questions? Health Economics. 2:1993;113-126.
48. Mitchell, J. B., Cromwell, J., 1997. Cost impact of clinical guidelines. Annual Meetings of the International Society of Technology Assessment in Health Care 13, 100.
49. MOH, 1986. Memorandum Health 2000 - On the development of health policy: Facts, discussions and policy plans. Ministry of Welfare, Health and Cultural Affairs, Rijswijk, Netherlands.
50. Mooney G., Creese A. Priority setting for health service efficiency: the role of measurement of burden of illness. Jamison D.T., Mosley W.H., Measham A.R., Bobadilla J.L. Disease control priorities in developing countries. 1993;Oxford University Press, Oxford.
51. Murray C., Kreuser J., Whang W. Cost-effectiveness analysis and policy choices: Investing in health systems. Murray C.J.L., Lopez A.D. Global comparative assessments in the health sector. 1994;World Health Organisation, Geneva.
52. Murray C.J. Toward an analytical approach to health sector reform. Health Policy. 32:1995;93-109.
53. Murray C.J., Lopez A.D. Evidence-based health policy lessons from the Global Burden of Disease Study. Science. 274:1996;740-743.
54. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020; the Global Burden of Disease Study. Lancet. 349:1997;1498-1504.
55. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 349:1997;1436-1442.
56. NERA, 1993. The economics of health reform: a prototype. National Economic Research Associates, London.
57. Niessen, L. W., Casparie, A. F., 2000. [Cost-effectiveness in integrated diabetes care - an economic evaluation of diabetes guidelines - ]. Dutch Diabetes Association/Dutch Institute for Health Care Improvement. van Zuiden Communications, Alphen a/d Rijn, the Netherlands. In press.
58. Niessen L.W., Hilderink H.B.M. The population health submodel. Rotmans J., de Vries B. Perspectives on global change: The TARGETS approach. 1997;57-81 Cambridge University Press, Cambridge.
59. Parmigiani G., Samsa G.P., Ancukiewicz M., Lipscomb J., Hasselblad V., Machtar D.B. Assessing uncertainty in cost-effectiveness analyses: Application to a complex decision model. Medical Decision Making. 17:1997;390-401.
60. Patrick, D. J., Erickson, P., 1993. Health status and health policy - Quality of life in health care evaluation and resource allocation. New York/Oxford: Oxford University Press.
61. Posnett J., Street A. Programme budgeting and marginal analysis: An approach to priority setting in need of refinement. Journal of Health Services Research and Policy. 1:1996;147-153.
62. Power E.J., Eisenberg J.M. Are we ready to use cost-effectiveness analysis in health care decision-making? A health services research challenge for clinicians, patients, health care systems, and public policy. Medical Care. 36:1998;S10-S147.
63. Preston S.H. The changing relation between mortality and level of economic development. Population Studies. 29:1975;231-248.
64. Pritchett L., Summers L. Wealthier is healthier. Journal of Human Resources. 21:1997;841-868.
65. Raine R. Evidence-based policy: rhetoric and reality. Journal of Health Services Research and Policy. 3:1998;251-253.
66. Rather P.A., Green L.W., Frankish C.J., Chornik T. Setting the stage for health impact assessment. Journal of Public Health Policy. 18:1997;67-80.
67. Rosenbaum S., Frankford D.M., Moore B., Borzi P. Who should determine when health care is medically necessary? New England Journal of Medicine. 340:1999;229-232.
68. Rutten F.F.H. Economic evaluation and health care decision making. Health Policy. 36:1996;215-229.
69. Ruwaard D. Public health status and forecasts - The health status of the Dutch population over the period 1950-2010. 1994;National Institute of Public Health and the Environment (RIVM), The Hague.
70. Ruwaard D. Public health status and forecasts - Health, prevention and health care in the Netherlands until 2015. 1997;National Institute of Public Health and the Environment (RIVM), Utrecht.
71. Sackett D.L., Rosenberg W.M., Gray J.A., Haynes R.B., Richardson W.S. Evidence based medicine: what it is and what it isn't. British Medical Journal. 312:(7023):1996;71-72.
72. Scott-Samuel A. Health impact assessment - An idea whose time has come. British Medical Journal. 313:1996;183-184.
73. The health of the nation. A strategy for health in England. 1992;HMSO, London.
74. Shaneyfelt T.M., Mayo-Smith M.F., Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. Journal of the American Medical Association. 281:1999;1900-1905.
75. Shekelle P.G., Woolf S.H., Eccles M., Grimshaw J. Clinical guidelines: developing guidelines. British Medical Journal. 318:1999;593-596.
76. Sloan F.A., Grabowski H.G. The impact of cost-effectiveness on public and private policies in health care: An international perspective. Social Science and Medicine. 45:1997;505-510.
77. Smith R. NICE: A panacea for the NHS? British Medical Journal. 318:1999;823-824.
78. Stronks K., Strijbis A.M., Wendte J.F., Gunning-Schepers L.J. Who should decide? Qualitative analysis of panel data from public, patients, healthcare professionals, and insurers on priorities in health care. British Medical Journal. 315:1997;92-96.
79. Swart, R., Bakkes, J., Niessen, L. W., Rotmans, J., de Vries, H. 1995. Scanning the global environment: A framework and methodology for integrated environmental reporting and assessment for UNEP's reporting functions. United Nations Environmental Programme, Nairobi/New York.
80. Tugwell P., Bennett R.J., Sacket D.L., Haynes R.B. The measurement iterative loop: A framework of critical appraisal of need, benefit, and costs of health interventions. Journal of Chronic Diseases. 38:1985;339-351.
81. Udvarhelyi S., Colditz G.A., Rai A., Epstein A.M. Cost-effectiveness and cost-benefit analyses in the medical literature. Are methods being used correctly? Annals of Internal Medicine. 116:1992;238-244.
82. Global Environmental Outlook - for life on earth. 1997;Oxford University Press, Oxford.
83. Identifying health technologies that work: Searching for the evidence. 1994;US Congress, Washington, DC.
84. USPHS, 1979. Health People 2000: Surgeon General's report on health promotion and diseases prevention. US Department of Health Education and Welfare; US Public Health Service, Washington.
85. Vallin J. Theories of mortality decline. van der Walle E., Pison G., Sala-Diakanda M. Mortality and society in sub-Saharan Africa. International studies in demography. 1992;Clarendon Press, Oxford.
86. Van der Maas P.J., de Koning H.J., Van Ineveld B.M., Oortmarssen G.J., Habbema J.D.F., Lubbe J.ThN, Geerts A.T., Colette H.J.A., Verbeek A.L.M., Hendriks J.H.C.L., Rombach J.J. The cost-effectiveness of breast cancer screening. International Journal of Cancer. 43:1989;1055-1060.
87. Van Doorslaer E., Wagstaff A. The redistributive effect of health care finance in twelve OECD countries. Journal of Health Economics. 18:1999;291-313.
88. Van Doorslaer E., Wagstaff A., Rutten F.F.H. Equity in the finance and delivery of health care: An international perspective. 1993;Oxford University Press, Oxford.
89. Van Hout B., Bonsel G., Habbema D., Van der Maas P., De Charro F. Heart transplantation in the Netherlands: Cost, effects and scenarios. Journal of Health Economics. 12:1993;73-93.
90. Van Os, N., Niessen, L. W., Bilo, H. J. G., Casparie, A. F., van Hout, B.A., 2000 Diabetes nephropathy in the Netherlands; a cost-effectiveness analysis of national clinical guidelines. Health Policy, 51(3), 135-147.
91. Wang L.Y., Haddix A.C., Teutsch S.M., Caldwell B. The role of resource allocation models in selecting clinical preventive services. American Journal of Managed Care. 5:1999;445-454.
92. WB, 1993. World Development Report - Investing in health. Washington, DC: World Bank.
93. Weil D.E., Alicbusan A.P., Wilson J.F., Reich M.R., Bradley D.J. The impact of development policies on health - A review of the literature. 1990;World Health Organisation, Geneva.
94. Wensing M., van der Weijden T., Grol R. Implementing guidelines and innovations in general practice: Which interventions are effective? British Journal of General Practicioners. 48:1998;991-997.
95. Health projections in Europe: Methods and applications. 1986;World Health Organisation Regional Office for Europe, Copenhagen.
96. The double burden: Emerging epidemics and persistent problems. World Health Report 1997 - Making a difference. 1997;World Health Organisation, Geneva.
97. Health and development in the 20th Century. World Health Report 1997 - Making a difference. 1997;World Health Organisation, Geneva.
98. Wolfe B., Gabay M. Health status and medical expenditures: more evidence of a link. Social Science and Medicine. 25:1987;883-888.
99. Woolf S.H., Grol R., Hutchinson A., Eccles M., Grimshaw J. Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. British Medical Journal. 318:1999;527-530.